Literature DB >> 9880516

A non-farnesylated Ha-Ras protein can be palmitoylated and trigger potent differentiation and transformation.

M A Booden1, T L Baker, P A Solski, C J Der, S G Punke, J E Buss.   

Abstract

Ha-Ras undergoes post-translational modifications (including attachment of farnesyl and palmitate) that culminate in localization of the protein to the plasma membrane. Because palmitate is not attached without prior farnesyl addition, the distinct contributions of the two lipid modifications to membrane attachment or biological activity have been difficult to examine. To test if palmitate is able to support these crucial functions on its own, novel C-terminal mutants of Ha-Ras were constructed, retaining the natural sites for palmitoylation, but replacing the C-terminal residue of the CAAX signal for prenylation with six lysines. Both the Ext61L and ExtWT proteins were modified in a dynamic fashion by palmitate, without being farnesylated; bound to membranes modestly (40% as well as native Ha-Ras); and retained appropriate GTP binding properties. Ext61L caused potent transformation of NIH 3T3 cells and, unexpectedly, an exaggerated differentiation of PC12 cells. Ext61L with the six lysines but lacking palmitates was inactive. Thus, farnesyl is not needed as a signal for palmitate attachment or removal, and a combination of transient palmitate modification and basic residues can support Ha-Ras membrane binding and two quite different biological functions. The roles of palmitate can therefore be independent of and distinct from those of farnesyl. Reciprocally, if membrane association can be sustained largely through palmitates, farnesyl is freed to interact with other proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880516     DOI: 10.1074/jbc.274.3.1423

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Multiple sequence elements facilitate Chp Rho GTPase subcellular location, membrane association, and transforming activity.

Authors:  Emily J Chenette; Natalia Y Mitin; Channing J Der
Journal:  Mol Biol Cell       Date:  2006-04-26       Impact factor: 4.138

Review 2.  In vitro and cellular assays for palmitoyl acyltransferases using fluorescent lipidated peptides.

Authors:  Charles E Ducker; Jeremiah M Draper; Zuping Xia; Charles D Smith
Journal:  Methods       Date:  2006-10       Impact factor: 3.608

3.  Dual lipid modification of Arabidopsis Ggamma-subunits is required for efficient plasma membrane targeting.

Authors:  Qin Zeng; Xuejun Wang; Mark P Running
Journal:  Plant Physiol       Date:  2007-01-12       Impact factor: 8.340

4.  Discovery and characterization of inhibitors of human palmitoyl acyltransferases.

Authors:  Charles E Ducker; Lindsay K Griffel; Ryan A Smith; Staci N Keller; Yan Zhuang; Zuping Xia; John D Diller; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

Review 5.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

6.  H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway.

Authors:  A Apolloni; I A Prior; M Lindsay; R G Parton; J F Hancock
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

7.  Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase.

Authors:  Charles E Ducker; Erin M Stettler; Kevin J French; John J Upson; Charles D Smith
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

8.  The human SNARE protein Ykt6 mediates its own palmitoylation at C-terminal cysteine residues.

Authors:  Michael Veit
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

9.  Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway.

Authors:  J Shawn Goodwin; Kimberly R Drake; Carl Rogers; Latasha Wright; Jennifer Lippincott-Schwartz; Mark R Philips; Anne K Kenworthy
Journal:  J Cell Biol       Date:  2005-07-18       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.